Grifols, S.A. $GRFS Holdings Increased by Brandes Investment Partners LP

Brandes Investment Partners LP lifted its holdings in Grifols, S.A. (NASDAQ:GRFS) by 6.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 30,954,223 shares of the biotechnology company’s stock after buying an additional 1,838,727 shares during the quarter. Grifols makes up about 2.2% of Brandes Investment Partners LP’s holdings, making the stock its 5th biggest holding. Brandes Investment Partners LP’s holdings in Grifols were worth $289,422,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Allworth Financial LP grew its position in shares of Grifols by 15.7% in the 4th quarter. Allworth Financial LP now owns 8,073 shares of the biotechnology company’s stock worth $75,000 after buying an additional 1,096 shares during the period. Cerity Partners LLC grew its position in shares of Grifols by 6.3% in the 4th quarter. Cerity Partners LLC now owns 19,121 shares of the biotechnology company’s stock worth $179,000 after buying an additional 1,131 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Grifols by 25.7% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,928 shares of the biotechnology company’s stock worth $55,000 after buying an additional 1,212 shares during the period. Savant Capital LLC grew its position in Grifols by 16.0% during the 3rd quarter. Savant Capital LLC now owns 14,011 shares of the biotechnology company’s stock valued at $140,000 after purchasing an additional 1,935 shares during the last quarter. Finally, Franklin Resources Inc. grew its position in Grifols by 10.9% during the 4th quarter. Franklin Resources Inc. now owns 21,343 shares of the biotechnology company’s stock valued at $200,000 after purchasing an additional 2,104 shares during the last quarter.

Grifols Price Performance

GRFS opened at $7.34 on Wednesday. The company has a debt-to-equity ratio of 1.16, a quick ratio of 0.85 and a current ratio of 2.47. The stock has a market capitalization of $5.00 billion, a P/E ratio of 38.63, a P/E/G ratio of 0.28 and a beta of 0.65. The company’s 50-day simple moving average is $8.04 and its two-hundred day simple moving average is $8.58. Grifols, S.A. has a 52-week low of $7.32 and a 52-week high of $11.14.

Grifols (NASDAQ:GRFS) last posted its earnings results on Saturday, February 14th. The biotechnology company reported $0.38 earnings per share (EPS) for the quarter. The business had revenue of $2.32 billion for the quarter. Grifols had a net margin of 5.54% and a return on equity of 6.21%. As a group, analysts predict that Grifols, S.A. will post 1.06 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently commented on GRFS. Zacks Research downgraded shares of Grifols from a “hold” rating to a “strong sell” rating in a research report on Friday, May 8th. Wall Street Zen downgraded shares of Grifols from a “buy” rating to a “hold” rating in a research report on Monday, May 18th. Finally, Weiss Ratings raised shares of Grifols from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, May 8th. Three equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Reduce” and an average target price of $10.00.

Grifols Profile

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.